Key Highlights
- Partner iECURE has completed dosing across all patient cohorts in the Phase 1/2 OTC-HOPE trial.
- ECUR-506, an ARCUS nuclease-based gene editing candidate, showed a generally favorable safety profile.
- Low-dose cohort patients showed meaningful metabolic stability and a 74% reduction in annual hyperammonemic crises.
- Evaluation of the high-dose cohort remains ongoing under the established licensing agreement.
Full Cohort Dosing Complete in a Partnered Program
Precision BioSciences Inc. (NASDAQ:DTIL) said its partner iECURE has completed dosing across all patient cohorts in the Phase 1/2 OTC-HOPE trial evaluating ECUR-506 for neonatal-onset Ornithine Transcarbamylase (OTC) deficiency, a rare and often life-threatening genetic condition that impairs the body's ability to clear ammonia from the blood. ECUR-506 is built on Precision BioSciences' ARCUS nuclease-based gene editing platform, which is licensed to iECURE under an established agreement covering this program's development.
Completing dosing across every planned cohort — rather than just the low-dose group — marks a meaningful step forward for the trial, since it means the full range of doses being tested has now been administered to enrolled patients.
Safety and Early Efficacy Signals
The company reported a generally favorable safety profile for ECUR-506 across the dosed cohorts. In the low-dose cohorts specifically, patients showed meaningful metabolic stability along with a 74% reduction in the annual rate of hyperammonemic crises — the acute, potentially life-threatening episodes of ammonia buildup that define the most severe risk in OTC deficiency. A reduction of this magnitude, if it holds up as more data matures, would represent a substantial change in disease management for a condition where crises can cause serious neurological harm.
What Remains Ongoing
While the low-dose cohort data is further along, evaluation of the high-dose cohort remains ongoing under the licensing agreement between Precision BioSciences (NASDAQ:DTIL) and iECURE. Data from the higher-dose group will be important for determining whether a stronger dosing regimen can extend the benefit seen at the lower dose without compromising the favorable safety profile observed so far.
Who is Precision BioSciences' partner on the OTC-HOPE trial?
iECURE is Precision BioSciences' (NASDAQ:DTIL) partner and has completed dosing across all patient cohorts in the Phase 1/2 OTC-HOPE trial.
What did low-dose cohort data show?
Low-dose cohort patients showed meaningful metabolic stability and a 74% reduction in the annual rate of hyperammonemic crises.
Is any part of the trial still ongoing?
Yes, evaluation of the high-dose cohort remains ongoing under the established licensing agreement.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...